Drug imperviousness to the basic antimalarial therapeutics of the artemisinin family has risen in Southeast Asia, highlighting the need to see how these medications work and how they can be utilized all the more successfully. Research now demonstrates that artemisinins may work by artificially harming the jungle fever parasite's proteins, making them actuate a cell stress reaction. Parasites impervious to artemisinins have built up a more overwhelming anxiety reaction, making them impenetrable to the ordinary medication medications. Then again, it creates the impression that with delayed artemisinin treatment, even this enhanced anxiety reaction can be overpowered, prompting parasite leeway. This work proposes that expanding artemisinin treatment or co-overseeing medications that focus on the anxiety reaction can overcome drug resistance. The WHO, in their Global Plan for Artemisinin Resistance Containment, expresses that "There is a limited window of chance to contain artemisinin resistance. In the event that the ebb and flow foci of artemisinin-safe parasites are not contained or wiped out, the expenses, both human and budgetary, could be incredible." The exploration of Professor Tilley and partners makes a vital step towards keeping the spread of medication resistance by distinguishing medicines that can slaughter safe parasites.